Aperiomics’ Xplore-COVID-19™ Testing detects Coronavirus – SARS-CoV-2. Aperiomics and related services are performed to CLIA and GMP medical device quality standards by Aperiomics, Inc. and/or related partners. This test must be ordered and collected by a healthcare provider.

For up to date information on COVID-19, please refer to the CDC website at https://www.cdc.gov/coronavirus/2019-ncov/summary.html.

Turnaround Time: 12-48 hours, striving for same-day turnaround time when possible

Cost: $140 per sample
We now offer Medicare billing! Medicare patients pay nothing out of pocket for COVID-19 testing with Aperiomics. All other patients pay up front. We provide an invoice to patients for patient-submitted private insurance reimbursement.

Testing Method: RT-PCR to identify SARS-CoV-2 viral RNA

Required Collection Kit: Aperiomics Cough Swab Collection Kit

Sample Collection Details: Per FDA regulations, the COVID-19 samples must be collected by a healthcare provider. Aperiomics utilizes a cough throat swab sample collection. Once the cough swab sample is collected and put into the DNA/RNA Shield vial, all microorganisms on the swab are inactivated and no longer infectious. Our sample collection method stabilizes viral RNA for up to 30 days at ambient temperatures.

Testing Details: COVID-19 virus nucleic acid is extracted from cough swab samples. Real-time reverse transcriptase PCR (RT-PCR) is performed by use of 1-step reverse transcription of RNA from the sample and then amplified by PCR. Internal positive and negative controls are included to ensure that each test performs correctly. The US Centers for Disease Control and Prevention (CDC) designed RT-PCR assays for the detection of 2019-nCoV. Our test uses the same primers and probes used in CDC assays and has comparable in sensitivity and specificity to CDC assays. Sensitivity is ~98% and specificity is ~99.9%.

Aperiomics has submitted an application for FDA EUA (for emergency use) for Xplore-COVID-19™ testing. The testing is only for the detection of RNA from COVID-19 virus and not for any other viruses or pathogens.

Current Capacity: up to 2,500 samples per week

Order collection kits by email orders@aperiomics.com or call 703-229-0406

LIMITATIONS OF TESTING: Negative results do not preclude SARS2/COVID-19 virus infection and should not be used as the sole basis for treatment or other patient management decisions. Optimum specimen types and timing for peak viral levels during infections caused by SARS2/COVID-19 virus have not been determined. Collection of multiple specimens (types and time points) from the same patient may be necessary to detect the virus. A false negative result may occur if a specimen is improperly collected, transported or handled. False negative results may also occur if amplification inhibitors are present in the specimen or if inadequate numbers of organisms are present in the specimen. If the virus mutates in the RT-PCR target region, SARS2/COVID-19 virus may not be detected or may be detected less predictably. Inhibitors or other types of interference may produce a false negative result. Test performance can be affected because the epidemiology and clinical spectrum of infection caused by SARS2/COVID-19 virus is not fully known. Detection of viral RNA may not indicate the presence of infectious virus or that SARS2/COVID-19 virus is the causative agent for clinical symptoms. This test cannot rule out diseases caused by other bacterial or viral pathogens. Negative results must be combined with clinical observations, patient history, and epidemiological information by your healthcare provider. Aperiomics, Inc. is required by law to maintain the privacy and security of your protected health information. COVID-19 testing is performed under CLIA/GAP standards by Aperiomics, Inc. and selected partners. This test is for the detection of RNA from the SARS2/COVID-19 virus, not for any other viruses or pathogens. The test has been validated, but FDA’s independent review of this validation is pending. APERIOMICS is a trademark of Aperiomics, Inc. © 2020 Aperiomics, Inc. All rights reserved.